Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Thera...
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Business Wire
CINCINNATI--(BUSINESS WIRE)--Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS).ASHA-624 was designed using Asha’s proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cures for difficult to treat diseases with high unmet medical need. ASHA-624 prevents the loss of nerve cell projections (axons) by selectively “gluing” the central regulator of axon degeneration, SARM1 into an inactive state, a mechanism of action which represents an ind
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- New Alzheimer's prevention trial receives $74.5 million NIH grant [Yahoo! Finance]Yahoo! Finance
- 2 Top Growth Stocks to Buy on the Dip [Yahoo! Finance]Yahoo! Finance
- Lung Cancer Therapy Research Report 2024: Demand for Targeted Therapy, Arrival of Nanomedicine, Emergence of New Diagnostics and Advanced Therapies, Growth of Combination Therapy - Forecasts to 2029 [Yahoo! Finance]Yahoo! Finance
- 3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years [Yahoo! Finance]Yahoo! Finance
- Lilly expands R&D footprint in Singapore with SGD$42 million investment in new Digital Health Innovation Hub [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 11/8/24 - Form 144
- 11/8/24 - Form 4
- 11/5/24 - Form 4
- LLY's page on the SEC website